Although Drp1(16/17) and Drp1(-/17) transcript variants are both abundant in ovarian cancer cell lines and patient specimens, the above data suggest that their relative expression has consequences on ovarian cancer progression. This evidence concerns the gene DNM1L and ovarian carcinoma.